白细胞介素17相关生物制剂治疗银屑病过程中浅部真菌感染的发生及应对策略  

Superficial fungal infections in psoriasis patients treated with IL-17 related biological agents and their management

作　　者：王晓雯[1] 李若瑜[1] Wang Xiaowen;Li Ruoyu(Department of Dermatology and Venereology,Peking University First Hospital,Research Center for Medical Mycology,Peking University,Beijing Key Laboratory of Molecular Diagnosis of Dermatoses,National Clinical Research Center for Skin and Immune Diseases,Beijing 100034,China)

机构地区：[1]北京大学第一医院皮肤性病科北京大学真菌和真菌病研究中心皮肤病分子诊断北京市重点实验室国家皮肤与免疫疾病临床医学研究中心,北京100034

出　　处：《中华皮肤科杂志》2022年第3期272-275,共4页Chinese Journal of Dermatology

摘　　要：本文综述白细胞介素(IL)-17与皮肤黏膜真菌感染易感性的基本机制, 以及与IL-17相关的生物制剂, 如司库奇尤单抗、依奇珠单抗、布罗达单抗、拜莫克珠单抗和乌司奴单抗在治疗银屑病中发生的浅部真菌感染。与IL-17相关生物制剂治疗相关的浅部真菌感染以轻度或中度为主, 多呈局限性, 且抗真菌治疗效果良好。此外, 本文介绍了对相关浅部真菌感染的临床评估、监控与治疗措施, 为IL-17类生物制剂临床安全用药提供依据。This review summarizes the contribution of interleukin-17(IL-17)to the susceptibility to mucocutaneous fungal infections,and superficial fungal infections associated with IL-17-targeting biological agents,such as secukinumab,ixekizumab,brodalumab,bimekizumab and ustekinumab,in the treatment of psoriasis.The superficial fungal infections related to the treatment with IL-17 monoclonal antibody agents are usually mild or moderate,and most of them are limited,with a good response to anti-fungal therapy.In addition,this review introduces clinical evaluation,monitoring and treatment of related superficial fungal infections,and provides a basis for safe clinical use of IL-17-targeting biologics.

关 键 词：银屑病 生物制剂 白细胞介素17 药物毒性 念珠菌病 皮肤 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]